PubMed

Factors associated with virological response to etravirine in non nucleoside reverse transcriptase inhibitor experienced HIV-1 infected patients.

Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V; the ANRS AC11 Resistance study group.

Antimicrob Agents Chemother. 2009 Nov 9. [Epub ahead of print]PMID: 19901096 [PubMed - as supplied by publisher]Related articles

Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets.

Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola D; on behalf of the Standardization, Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research.

AIDS. 2009 Oct 27. [Epub ahead of print]PMID: 19864933 [PubMed - as supplied by publisher]Related articles

Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.

Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, Jaeger H, Shürmann D, Cohen-Codar I, Van PN, Norton M, Taburet AM, Delfraissy JF, Rouzioux C; MONARK Study Group.

Antimicrob Agents Chemother. 2009 Jul;53(7):2934-9. Epub 2009 May 18.PMID: 19451297 [PubMed - indexed for MEDLINE]Related articles

Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone.

Flandre P, Delaugerre C, Ghosn J, Chaix ML, Horban A, Girard PM, Gladysz A, Cohen-Codar I, Van PN, Taburet AM, Rouzioux C, Delfraissy JF; MONARK Study Group.

Antivir Ther. 2009;14(1):93-7.PMID: 19320241 [PubMed - indexed for MEDLINE]Related articles

Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.

Marcelin AG, Flandre P, Molina JM, Katlama C, Yeni P, Raffi F, Antoun Z, Ait-Khaled M, Calvez V.

Antimicrob Agents Chemother. 2008 Dec;52(12):4251-7. Epub 2008 Oct 13.PMID: 18852278 [PubMed - indexed for MEDLINE]Related articlesFree article

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.

Lambert-Niclot S, Flandre P, Malet I, Canestri A, Soulié C, Tubiana R, Brunet C, Wirden M, Katlama C, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2008 Nov;62(5):905-8. Epub 2008 Sep 1.PMID: 18765410 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.

Spire B, Marcellin F, Cohen-Codar I, Flandre P, Boue F, Dellamonica P, Raffi F, Norton M, Van Philippe N, Delfraissy JF.

Antivir Ther. 2008;13(4):591-9.PMID: 18672538 [PubMed - indexed for MEDLINE]Related articles

Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.

Marcelin AG, Masquelier B, Descamps D, Izopet J, Charpentier C, Alloui C, Bouvier-Alias M, Signori-Schmuck A, Montes B, Chaix ML, Amiel C, Santos GD, Ruffault A, Barin F, Peytavin G, Lavignon M, Flandre P, Calvez V.

Antimicrob Agents Chemother. 2008 Sep;52(9):3237-43. Epub 2008 Jul 14.PMID: 18625773 [PubMed - indexed for MEDLINE]Related articlesFree article

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP.

AIDS. 2008 Jan 30;22(3):385-93.PMID: 18195565 [PubMed - indexed for MEDLINE]Related articles

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.

Lambert-Niclot S, Flandre P, Canestri A, Peytavin G, Blanc C, Agher R, Soulié C, Wirden M, Katlama C, Calvez V, Marcelin AG.

Antimicrob Agents Chemother. 2008 Feb;52(2):491-6. Epub 2007 Nov 26.PMID: 18039922 [PubMed - indexed for MEDLINE]Related articlesFree article

Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.

Marcelin AG, Flandre P, de Mendoza C, Roquebert B, Peytavin G, Valer L, Wirden M, Abbas S, Katlama C, Soriano V, Calvez V.

Antivir Ther. 2007;12(2):247-52.PMID: 17503666 [PubMed - indexed for MEDLINE]Related articles

Predictive strength of Jonckheere's test for trend: an application to genotypic scores in HIV infection.

Flandre P, O'Quigley J.

Stat Med. 2007 Oct 30;26(24):4441-54.PMID: 17397042 [PubMed - indexed for MEDLINE]Related articles

Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.

Marcelin AG, Flandre P, Furco A, Wirden M, Molina JM, Calvez V; AI454-176 Jaguar Study Team.

Antivir Ther. 2006;11(6):693-9.PMID: 17310813 [PubMed - indexed for MEDLINE]Related articles

Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection.

Flandre P, Chappey C, Marcelin AG, Ryan K, Maa JF, Bates M, Seekins D, Bernard MC, Calvez V, Molina JM.

J Infect Dis. 2007 Feb 1;195(3):392-8. Epub 2006 Dec 21.PMID: 17205478 [PubMed - indexed for MEDLINE]Related articles

On the comparison of artificial network and interpretation systems based on genotype resistance mutations in HIV-1-infected patients.

Flandre P, Costagliola D.

AIDS. 2006 Oct 24;20(16):2118-20.PMID: 17053360 [PubMed - indexed for MEDLINE]Related articles

Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials.

Flandre P, Pinçon C, Aboulker JP, Brun-Vézinet F, Pialoux G, Raffi F, Descamps D.

HIV Clin Trials. 2006 May-Jun;7(3):116-24.PMID: 16880168 [PubMed - indexed for MEDLINE]Related articlesFree article

Quantification of the prentice criteria for surrogate endpoints.

O'Quigley J, Flandre P.

Biometrics. 2006 Mar;62(1):297-300.PMID: 16542258 [PubMed - indexed for MEDLINE]Related articles

Predictors of virologic response to ritonavir-boosted protease inhibitors.

Marcelin AG, Flandre P, Peytavin G, Calvez V.

AIDS Rev. 2005 Oct-Dec;7(4):225-32. Review.PMID: 16425962 [PubMed - indexed for MEDLINE]Related articles

Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.

Vora S, Marcelin AG, Günthard HF, Flandre P, Hirsch HH, Masquelier B, Zinkernagel A, Peytavin G, Calvez V, Perrin L, Yerly S; Swiss HIV Cohort Study.

AIDS. 2006 Jan 2;20(1):35-40.PMID: 16327317 [PubMed - indexed for MEDLINE]Related articles

Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study.

Flandre P, Marcelin AG, Pavie J, Shmidely N, Wirden M, Lada O, Bernard MC, Molina JM, Calvez V.

Antivir Ther. 2005;10(4):479-87.PMID: 16038473 [PubMed - indexed for MEDLINE]Related articles